SX
SXTPW
60 DEGREES PHARMACEUTICALS, INC.Warrants of 60 DEGREES PHARMACEUTICALS, INC. · SXTP stock page →
—
Market cap
$89.0K
Nano cap
1 year
−85.1%
from $5.92 · Oct 27
30 days
−29.6%
from $1.25
52-week range
$0.8270–5.92
−85% from high · low Oct 19
Avg volume 20D
213.4K
Oct 6 spike 2.45M
Short interest
1.1K
≈0.0% of shares · −42.9%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 26 FDA: 60 Degrees Pharmaceuticals Announces Early Enrollment of F…
- E Jul 1 FDA: 60 Degrees Pharmaceuticals Announces Positive Recommendati…
- E Jul 30 Offering: 60 Degrees Pharmaceuticals, Inc. Announces Private Placeme…
- X Aug 31 Short interest jumps 130.0% to 1.9K
- X Sep 30 Short interest falls 42.9% to 1.1K
- E Oct 6 FDA: 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −42.9% to 1.1K shares. 1.0 days to cover, ≈0.0% of shares.
- TrendDOWNTREND
15% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | $329.00 |
| UBS Group AG | TRIM | $30.00 |
| UBS Group AG | DOUBLED | $15.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 6, 2026
FDA
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sNDA meeting with FDA.
Oct 1, 2026
Press release
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
60 Degrees Pharmaceuticals will release interim severe babesiosis study data and host a KOL investor webinar on October 6, 2026.
Aug 14, 2026
Earnings
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Jul 30, 2026
Offering
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Jul 8, 2026
Press release
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $270.0K |
| Next Q | — | — | — | $310.0K |
| Current FY | — | — | — | $1.0M |
| Next FY | — | — | — | $1.7M |
Short side
FINRA· Sep 30, 20261,102
shares short
-42.9%
vs prior settlement
1.0
days to cover
≈0.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 FDA
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sND
Jun 30, 2026 Inst.
May 19, 2026 SEC SUSQUEHANNA INTERNATIONAL GROUP, LLP — TRIM
10,892 shares ($329.00)
Eric Francois filed a Form 3 initial statement of beneficial ownership reporting zero securities owned in 60 Degrees…
3 — Impact 3/10
Sep 30, 2025 Inst.
UBS Group AG — TRIM
814 shares ($30.00)
SecBot reports
1 filing · 0 bullish · 0 bearish · 1 neutralAll SXTPW filing & press-release reports (1)
- 3 reportMay 19, 2026